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Background and Purpose—Endovascular embolization of intracranial aneurysms with hydrogel-coated coils lowers the 
risk of major recurrence, but technical limitations (coil stiffness and time restriction for placement) have prevented their 
wider clinical use. We aimed to assess the efficacy of softer, second-generation hydrogel coils.
Methods—A randomized controlled trial was conducted at 22 centers in France and Germany. Patients aged 18 to 75 years 
with untreated ruptured or unruptured intracranial aneurysms measuring 4 to 12 mm in diameter were eligible and 
randomized (1:1 using a web-based system, stratified by rupture status) to coiling with either second-generation hydrogel 
coils or bare platinum coils. Assist devices were allowed as clinically required. Independent imaging core laboratory 
was masked to allocation. Primary end point was a composite outcome measure including major aneurysm recurrence, 
aneurysm retreatment, morbidity that prevented angiographic controls, and any death during treatment and follow-up. 
Data were analyzed as randomized.
Results—Randomization began on October 15, 2009, and stopped on January 31, 2014, after 513 patients (hydrogel, n=256; 
bare platinum, n=257); 20 patients were excluded for missing informed consent and 9 for treatment-related criteria. 
Four hundred eighty-four patients (hydrogel, n=243; bare platinum, n=241) were included in the analysis; 208 (43%) 
were treated for ruptured aneurysms. Final end point data were available for 456 patients. Forty-five out of 226 (19.9%) 
patients in the hydrogel group and 66/230 (28.7%) in the control group had an unfavorable composite primary outcome, 
giving a statistically significant reduction in the proportion of an unfavorable composite primary outcome with hydrogel 
coils—adjusted for rupture status—of 8.4% (95% confidence interval, 0.5–16.2; P=0.036). Adverse and serious adverse 
events were evenly distributed between groups.
Conclusions—Our results suggest that endovascular coil embolization with second-generation hydrogel coils may reduce 
the rate of unfavorable outcome events in patients with small- and medium-sized intracranial aneurysms.
Clinical Trial Registration—URL: https://www.drks.de/drks_web/. Unique identifier: DRKS00003132.   
(Stroke. 2018;49:667-674. DOI: 10.1161/STROKEAHA.117.018707.)
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Endovascular coil embolization is the preferred treatment modality for many patients with intracranial aneurysms 
because the results of the ISAT (International Subarachnoid 
Aneurysm Trial) showed better clinical outcomes with endo-
vascular coiling than neurosurgical clipping in patients with 
ruptured aneurysms.1 Nevertheless, incomplete aneurysm 
occlusion or recanalization of completely occluded aneurysms 
may occur after endovascular coiling. In aneurysms treated 
with bare platinum coils, the recanalization rates reported in 
the literature ranged from 4.7% to 28%,2 and the rehemor-
rhage rates ranged from 0.12% to 0.4% per year.3,4
Earlier studies on aneurysm recanalization suggested a cor-
relation between packing density—the percentage of the aneu-
rysmal volume occluded with coils—and the recanalization 
rate.5 To enhance the durability of endovascular coiling, coated 
coils were brought to clinical practice. Platinum coils coated 
with polymers including polyglycolic acid/polylactic acid were 
meant to enhance the inflammatory response at the neck of the 
aneurysm, to promote organization of clot in the aneurysm and 
the formation of neointima at the neck, but the concept did not 
prove effective in 2 randomized controlled trials.6,7
A different approach consists of platinum coils coupled 
with hydrogel, which expands once in contact with liquids, 
resulting in increased packing density. The results of the 
HELPS (Hydrocoil Endovascular Aneurysm Occlusion and 
Packing Study) that assessed the efficacy and safety of a cor-
responding hybrid hydrogel-coated platinum detachable coil 
(HydroCoil; MicroVention, Inc, Tustin, CA) indicate that their 
use lowers major recurrence,8 but technical limitations of the 
HydroCoil (coil stiffness and time restriction for placement) 
have prevented its wider clinical use. To circumvent these lim-
itations, softer hydrogel coils (HydroSoft, HydroFrame [3D]; 
MicroVention, Inc) containing less hydrogel and expanding 
more slowly than the HydroCoil have been developed.
In GREAT (German-French Randomized Endovascular 
Aneurysm Trial), we aimed to establish whether the use of 
softer, second-generation hydrogel coils for the treatment of 
intracranial aneurysms improves clinical and angiographic 
outcomes compared with the use of bare platinum coils.
Methods
The data that support the findings of this study are available from the 
corresponding author on reasonable request.
Study Design
GREAT was an investigator-initiated, pragmatic, postmarket, multi-
center clinical trial with randomized parallel treatment group assign-
ments, open-label treatment, and blinded end point evaluation for 
angiographic data. The study was conducted in 15 centers in France 
and 7 in Germany. The study protocol was approved by the lead-
ing ethics committee (Faculty of Medicine, University of Freiburg, 
077/09) and the local ethics committees and was authorized by the 
competent French and German authorities. Members of the trial 
steering committee and the local investigators designed the study, 
collected and analyzed the data, wrote the article, and made the deci-
sion to submit the article for publication.
Patients
Patients were eligible for enrolment if they were 18 to 75 years of 
age and had untreated ruptured (World Federation of Neurosurgical 
Societies [WFNS] grade 0–3) or unruptured aneurysms measuring 
4 to 12 mm in diameter with an anatomy such that endovascular 
occlusion with either bare platinum or hydrogel coils was considered 
possible. We chose to restrict the aneurysm size because the larg-
est second-generation hydrogel coil available when the trial started 
measured 12 mm. Detailed inclusion and exclusion criteria are listed 
in the study protocol.9 We did not keep a log of patients screened for 
eligibility. All patients or their legal representatives provided written 
informed consent. In Germany, the ethics committee approved ran-
domization without prior informed consent, with the option to obtain 
consent at a later stage, but patients with missing informed consent 
were excluded from further analysis.
Randomization and Masking
Endovascular embolization of intracranial aneurysms with second-
generation hydrogel coils was compared with endovascular emboliza-
tion with bare platinum coils. Randomization occurred immediately 
before the study intervention. The randomization procedure was web 
based (Randoulette; Institute for Medical Informatics, Biometry, and 
Epidemiology, Ludwig-Maximilians-University, Munich, Germany). 
Allocation to a coil group was by block randomization in a 1:1 ratio, 
stratified by rupture status (ruptured versus unruptured aneurysm); 
block sizes were 2, 4, and 6. Centers were not informed about the 
block sizes. Masking of the interventional team to the randomly 
allocated treatment was not possible. Masking of patients was not 
mandatory; however, investigators were encouraged to refrain from 
unnecessary disclosure of treatment allocation.
Procedures
Participants in the intervention group underwent endovascular 
embolization with second-generation hydrogel coils (HydroSoft, 
HydroFrame; MicroVention, Inc). Standard local procedures for the 
coiling of aneurysms were followed. All procedures were performed 
under general anesthesia. Within the hydrogel arm of the study, sec-
ond-generation hydrogel coils had to constitute >50% of the total coil 
length deployed. Any bare platinum coils were permitted, as were 
assist devices such as remodeling balloons or endovascular stents. 
Only devices that had received Conformité Européenne marking were 
used in the trial. The antiplatelet and anticoagulation regimens were 
left to the discretion of the individual operator as part of the standard 
operation procedure at each center. Detailed information about the 
coiling procedure was reported elsewhere.10
Clinical and Radiological Assessments
All patients underwent clinical examination and angiographic assess-
ment of the underlying aneurysm. At the time of randomization, the 
following parameters were collected: sex, age, and rupture status 
(unruptured versus recently ruptured [<30 days]). Baseline data col-
lected included number of aneurysms, aneurysm size (in mm), aneu-
rysm neck size (in mm), dome-to-neck ratio, and aneurysm location. 
In patients with ruptured aneurysms, the WFNS grade was determined. 
After the coiling procedure, data were obtained on coils used, use of 
assist devices, disease- and procedure-related complications, and the 
initial angiographic outcome.10 Study data were entered locally by the 
treating physician or a dedicated study nurse into the trial database 
via web-based electronic case report forms. Digital copies of angio-
graphic images of the aneurysm before treatment, immediately after 
treatment, at 6-month follow-up, and at 18-month follow-up were 
sent to the trials office. Digital subtraction angiography was preferred 
to magnetic resonance angiography, but magnetic resonance angiog-
raphy was considered acceptable for centers where angiographic con-
trols routinely are performed with magnetic resonance angiography. 
Imaging data were entered into the picture archiving and communica-
tion system in a pseudonymised way and reviewed by the core labora-
tory (H.D. and J.F.), who were masked to both treatment allocation 
and treatment received. The core laboratory reviewed imaging data 
together and were asked to assess the degree of aneurysm occlusion 
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remnant, and residual aneurysm).11 A major recurrence was defined 
as any change from complete aneurysm occlusion or neck remnant at 
the end of the index procedure to residual aneurysm at angiographic 
follow-up. In patients with residual aneurysms at the end of the index 
procedure, major recurrence was defined as any increase in size of the 
residual aneurysm as judged by the independent core laboratory. The 
modified Rankin Scale (mRS) score was assessed by the team treat-
ing the patient during follow-up. The formulas used to calculate the 
total aneurysm volume, the volume of 1 coil, the total coil volume, 
and packing density have previously been published.10
Study End Points
Primary end point was a composite outcome of predefined unfavor-
able angiographic and clinical events. The composite primary end 
point included major aneurysm recurrence on follow-up angiography 
within 18 months after treatment (judged by a blinded core labora-
tory), any aneurysm retreatment, morbidity that prevented patients 
from having angiographic controls (mRS score, 3–5), and any death 
during treatment and follow-up. When angiographic results at 18 
months were not available, angiographic results at 6 months were 
used. In patients subject to >1 of the predefined unfavorable outcome 
events, only 1 was considered for the primary end point. In patients 
with retreatment or death during follow-up, the result of angiographic 
follow-up was disregarded for the composite primary end point. A 
composite angiographic and clinical end point was used rather than 
an angiographic end point alone because some patients die or are 
left so disabled after coiling or subarachnoid hemorrhage that they 
do not have follow-up angiographies. Secondary outcomes included 
clinical outcomes at 18 months using the mRS score, total coil length 
deployed, and coil packing density obtained. We did not compare 
the ease of use of second-generation hydrogel coils with that of bare 
platinum coils.
Statistical Analysis
The initially planned study size was 306 patients, but the target 
sample size was amended after the publication of the results of the 
HELPS, based on the assumption that unfavorable outcomes occur 
in 10% (hydrogel) versus 20% (bare platinum).8 Two hundred eigh-
teen patients per group were needed to detect this difference between 
hydrogel and bare platinum coils with a power of 80% using Fisher 
exact test at a 2-sided significance level of 5%. With expected non-
compliance or drop-out of patients after randomization in the order 
of 10%, 486 patients had to be randomized to observe the desired 
amount of compliant patients. The Trial Steering Committee decided 
to increase the target sample size to 500 patients in July 2012. This 
decision was driven exclusively by the external HELPS data.
Randomized patients without informed consent, patients who 
received flow-diverting stents or intrasaccular flow diverters, and 
patients in whom the intervention was stopped after the initial digi-
tal subtraction angiography were excluded. The lead investigator 
(C.A.T.) determined these treatment-based patient exclusions after 
final data cleaning of the database with respect to procedural data 
blinded for treatment allocation. Corresponding exclusions are indi-
cated in Figure 1 (aneurysm not accessible, no aneurysm found, 
received flow diverters, and received web devices). The remaining 
patients formed the analysis population in which nonmissing data 
were analyzed as randomized.
For binary outcomes, the absolute difference of the proportion of 
outcome events between the 2 arms, expressed as percentages, was 
calculated along with a 2-sided Newcombe 95% confidence interval 
(CI) and P value with Cochran–Mantel–Haenszel weights, stratified 
by rupture status.12 A preplanned sensitivity analysis of the primary 
end point explored the worst-case scenario in the analysis population 
where all missing outcomes for patients randomized to the hydrogel 
arm were evaluated as unfavorable and all those in the bare platinum 
arm as favorable. For post hoc analyses, we calculated Newcombe 
CI for the absolute difference in the proportion of unfavorable out-
comes between treatments within subgroups, and we examined odds 
ratios (±the interaction with treatment) by Wald tests from logistic 
regression. Ordinal and continuous data were compared using van 
Elteren Wilcoxon rank-sum test stratified for rupture status.13 Adverse 
events (AE) were evaluated by received treatment in the analysis pop-
ulation. Periprocedural AE and specific items requested in the elec-
tronic case report form describing treatment were evaluated jointly. 
AE with onset >14 days from initial aneurysm treatment were coded 
using the medical dictionary for regulatory activities. P values were 2 
sided and considered statistically significant if <0.05 and exploratory 
except for the primary analysis. All analyses were performed using 
version 9.2 of the Statistical Analysis System (SAS; SAS Institute, 
Cary, NC). The statistical analysis plan has been described in detail9 
(online-only Data Supplement).
Two interim analyses were undertaken, after randomization of 100 
and 300 patients, which included assessment of trial data on proce-
dure-related complications, postoperative degree of aneurysm occlu-
sion, AE, and mortality. Results of these analyses were reviewed by 
an independent data safety monitoring board in strict confidentiality, 
and relevant information from other sources was considered. The data 
safety monitoring board advised the lead investigator (C.A.T.) both 
times to continue with the trial. The primary end point had not been 
evaluated in the interim analyses.
Results
Baseline Results
From October 15, 2009, to January 31, 2014, 513 patients 
underwent randomization in 15 centers in France and 7 centers 
in Germany. Recruitment was stopped after the predetermined 
sample size was reached. Twenty-nine patients were excluded 
from the analysis population (Figure 1). The mean age of the 
484 patients in the analysis population was 52.4 years (range, 
21–82); 151 (31%) patients were men. Two hundred eight 
patients (43%) were treated for ruptured aneurysms. Two hun-
dred forty-three patients (50.2%) in the analysis population 
were assigned to the hydrogel group, and 241 (49.8%) were 
assigned to the bare platinum group. Among patients allocated 
to hydrogel, 5 were treated with bare platinum coils alone; 
among patients allocated to the control group, 6 received 
additional hydrogel coils. The use of assist devices (balloon 
remodeling and stent-assisted coiling) was balanced between 
the 2 arms of the study (Table 1). Potential risk factors for 
unfavorable angiographic and clinical outcomes (age, rupture 
status, WFNS grade ≥3, aneurysm dome-to-neck ratio <1.5, 
target aneurysm size, and target aneurysm neck size) were 
evenly distributed between the 2 treatment groups (Table 1).
AE and serious AE (SAE) collected during treatment and 
through to discharge included perforation, dissection or occlu-
sion of the parent vessel, procedure-related aneurysm rupture, 
thromboembolic events, stroke, coil migration, or procedure-
related AE with outcome death. AE and SAE with onset >14 
days from coiling were also collected.
Primary end point data were available in 456 patients 
(Figure 1).
Hydrogel Arm
Among patients allocated to the hydrogel group (n=243), 
103 (42%) were treated for ruptured aneurysms. Ninety-six 
patients (40%) were treated without the use of assist devices. 
Balloon remodeling alone was used in 88 patients (36%), 
stent-assisted coiling alone in 18 patients (7%), and both 
balloon remodeling and stent-assisted coiling in 41 patients 
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controls (n=239), 130 (54%) aneurysms were completely 
occluded, 47 (20%) showed a neck remnant, and 62 (26%) 
were residual aneurysms.
Primary end point data for the analysis population were 
available in 226 of 243 patients. Of 226 patients, 28 (12%) had 
major aneurysm recurrences, 7 (3%) had aneurysm retreat-
ment, 3 (1%) had morbidity that prevented them from having 
angiographic follow-up, and 7 (3%) died. AE and SAE occur-
ring during treatment through to discharge were reported in 
31 patients. AE and SAE with onset >14 days from coiling 
were reported in 20 patients. Hydrocephalus was reported in 2 
patients (Tables I and II in the online-only Data Supplement).
Bare Platinum Arm
Among patients allocated to the bare platinum arm (n=241), 
105 (44%) were treated for recently ruptured aneurysms. One 
hundred and ten patients (46%) were treated without the use 
of assist devices. Balloon remodeling alone was used in 81 
patients (34%), stent-assisted coiling alone was performed 
in 21 patients (9%), and both balloon remodeling and stent-
assisted coiling in 29 patients (12%). On core laboratory–
assessed final angiographic controls (n=237), 124 (52%) 
aneurysms were completely occluded, 55 (23%) showed a 
neck remnant, and 58 (24%) were residual aneurysms. These 
results did not differ significantly from those in the hydrogel 
arm (P=0.80).
Primary end point data for the analysis population were 
available in 230 of 241 patients allocated to the bare platinum 
arm of the study. Of 230 patients, 42 (18%) had major aneu-
rysm recurrences, 14 (6%) had aneurysm retreatment, and 10 
(4%) died. AE and SAE occurring during treatment through 
to discharge were reported in 27 patients. AE and SAE with 
onset >14 days from coiling were reported in 17 patients. 
Hydrocephalus was reported in 1 patient (Tables I and II in the 
online-only Data Supplement).
Six-month instead of 18-month angiographic controls were 
used for 31 (14.3%) of 217 patients in the hydrogel arm with 
available angiographic results and 50 (22.6%) of 221 patients 
in the control group.
Primary and Secondary End Point Results
There was a shift in the distribution of the unfavorable com-
posite primary outcome toward the control group (Table 2). 
This difference was statistically significant: among patients 
with recently ruptured aneurysms, 27 (28.7%) of 94 in the 
hydrogel group versus 38 (37.6%) of 101 in the control group 
experienced unfavorable composite primary outcome, yield-
ing an absolute increase in the risk of unfavorable composite 
primary outcome in the control group of 8.9% (95% CI, −4.3 
to 21.6; P=0.19). Among patients with unruptured aneurysms, 
18 (13.6%) of 132 in the hydrogel group versus 28 (21.7%) of 
129 in the control group experienced unfavorable composite 
primary outcome, yielding an absolute increase in the risk of 
unfavorable composite primary outcome in the control group 
of 8.1% (95% CI, −1.2 to 17.3; P=0.089).
Adjusted for rupture status by stratified analysis, the abso-
lute increase in the risk of unfavorable composite primary 
outcome for the control arm was 8.4% (95% CI, 0.5–16.2; 
P=0.036; number needed to treat, 12; relative increase, odds 
ratio, 1.61; 95% CI, 1.04–2.50; P=0.034).
Subgroup analysis stratifying for rupture status (ruptured 
versus unruptured) and aneurysm size (aneurysm size <10 
Figure 1. Trial profile. Centers did not 
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versus ≥10 mm) showed that the effect of second-generation 
hydrogel coils seemed more pronounced in unruptured aneu-
rysms and in aneurysms <10 mm (Figure 2).
A sensitivity analysis was performed under a worst-case 
scenario: for additional 28 patients of the analysis population 
with missing primary outcome data, we assumed an unfavor-
able composite primary outcome for patients in the hydrogel 
group and a favorable outcome for patients in the control 
group. The sensitivity analysis failed to show a statistically 
significant increase in the risk of unfavorable composite pri-
mary outcome in the control group (1.7%; 95% CI, −9.5 to 
6.2; P=0.67).
Angiographic outcomes at follow-up are displayed in Table 
III in the online-only Data Supplement. The test for between-
group differences in the 7-level mRS score for the clinical 
status at 18 months was not statistically significant (P=0.76; 
Table IV in the online-only Data Supplement). Greater aneu-
rysm packing density was achieved in the hydrogel group 
(median, 39%; range, 8–152) than in controls (median, 31%; 
range, 6–95). This difference was statistically significant 
(P<0.001). The analysis of administered coil lengths showed 
a nonsignificant trend that less total coil length was adminis-
tered in the hydrogel arm (median, 38 cm; range, 2–259) than 
in the control arm (median, 41 cm; range, 3–352; P=0.065).
Procedural complications occurred in 31 (12.7%) patients 
treated with hydrogel coils and 30 (12.4%) who received plati-
num coils (rate difference, 1.6%; 95% CI, −4.2 to 7.5; P=0.59). 
Procedure-related stroke or death occurred in 9 patients (3.7%) 
treated with hydrogel coils and 7 patients (2.9%) who had 
received bare platinum coils (Table I in the online-only Data 
Supplement). The 14-day mortality rates were comparable in 
both arms of the study: 5 patients per arm (2.0% versus 2.1%; 
rate difference, 0.1%; 95% CI, −3.2 to 3.1; P=0.96). There 
was no significant between-group difference in the occurrence 
Table 1. Demographic and Baseline Characteristics by 
Randomized Treatment
Randomized Treatment
Hydrogel Coils, n (%)
Bare Platinum 
Coils, n (%)
Total no. of patients 243 241
Sex
  Female 172 (71) 161 (67)
  Male 71 (29) 80 (33)
Age, y
  Mean±SD, range 52.9±12.6 (24–79) 54.1±11.8 (21–82)
Baseline rupture status
  Yes, in previous 30 d 103 (42) 105 (44)
  No 140 (58) 136 (56)
WFNS scores in patients with previously ruptured aneurysms 
  WFNS 1 65 (64) 74 (71)
  WFNS 2 21 (21) 15 (14)
  WFNS 3 11 (11) 11 (11)
  WFNS 4 4 (4) 3 (3)
  WFNS 5 1 (1) 1 (1)
  Missing n=1 n=1
Aneurysm location 
  Anterior 177 (74) 182 (76)
  Posterior/other 62 (26) 56 (24)
  Missing n=4 n=3
Target aneurysm size, mm
  Median, range 7 (2–15) 7 (2–18)
  Mean±SD, range 6.8±2.1 (2–15) 7.1±2.5 (2–18)
  Missing n=1 n=0
Size aneurysm neck, mm 
  Mean±SD, range 3.5±1.3 (1–8) 3.6±1.3 (2–9)
  Missing n=5 n=4
Dome-to-neck ratio
  <1.5 90 (38) 90 (38)
  ≥1.5 147 (62) 150 (63)
  Missing n=6 n=1
Aneurysm shape 
  Regular 136 (56) 133 (55)
  Irregular/lobulated 107 (44) 107 (45)
  Missing n=0 n=1
Assist device used 
  None 96 (40) 110 (46)
  Balloon, no stent 88 (36) 81 (34)
  Stent, no balloon 18 (7) 21 (9)
  Balloon+stent 41 (17) 29 (12)
WFNS indicates World Federation of Neurosurgical Societies.







  No major aneurysm recurrence on 
angiographic follow-up
181 (80) 164 (71)
Unfavorable, n (%) 
  Major aneurysm recurrence on 
angiographic follow-up without 
retreatment
28 (12) 42 (18)
  Retreatment 7 (3) 14 (6)
  No angiographic follow-up because of 
morbidity, mRS, 3–5
3 (1) 0
  Any death, mRS score 6 7 (3) 10 (4)
Refused or lost to angiographic follow-up 17 11
Data are represented as n (%). In 81 (18%) patients, 31 (14.3%) from the 
hydrogel arm and 50 (22.6%) from the control arm), 6-month angiographic 
results were used because 18-month angiography was not done or available. 
In patients with retreatment or death during follow-up, the result of any 
angiographic follow-up was disregarded for the composite primary end point. 
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of AE and SAE during the 18-month follow-up period (Table 
II in the online-only Data Supplement).
Twelve deaths (5 in the hydrogel group and 7 in the con-
trol group) occurred in the subgroup of patients with recently 
ruptured aneurysms and available clinical follow-up (n=195). 
Seven additional patients with recently ruptured aneurysms 
had poor clinical outcomes (mRS score, 3–5; 5 in the hydrogel 
group and 2 in the control group). In the subgroup of patients 
with incidental aneurysms and available clinical follow-up 
(n=270), 5 deaths (2 in the hydrogel group and 3 in the con-
trol group) occurred. Three additional patients with incidental 
aneurysms (2 in the hydrogel arm and 1 in the control group) 
had poor clinical outcomes (mRS score, 3–5). This results 
in a morbidity and mortality rate (mRS score ≥3) of 9.6% 
for patients with recently ruptured aneurysms and 3.0% for 
patients with incidental aneurysms.
Discussion
In this study, the risk of meeting the unfavorable composite 
primary end point of major angiographic recurrence and poor 
clinical outcome at 18 months after treatment was signifi-
cantly lower in patients treated with second-generation hydro-
gel coils than in the control group of patients treated with bare 
platinum coils.
Our findings stand in clear distinction to those of recent 
randomized controlled trials on embolization with polygly-
colic acid/polylactic acid-coated coils for the treatment of 
intracranial aneurysms that failed to show a benefit when 
compared with bare platinum coils.6,7 The results of 2 other 
randomized controlled trials on embolization with hydro-
gel coils showed variable results.8,14 HELPS, which inves-
tigated the effectiveness of first-generation hydrogel coils 
(HydroCoils; MicroVention, Inc), failed to show significant 
differences for the composite primary end point of the trial. 
Analysis of a secondary end point showed an 8.6% reduc-
tion in major recurrences for aneurysms treated with hydro-
gel coils when compared with aneurysms treated with bare 
platinum coils.8 The PRET trial (Patients Prone to Recurrence 
After Endovascular Treatment) analyzed the potential effect 
of first- and second-generation hydrogel coils on 2 differ-
ent cohorts: patients with large aneurysms (PRET 1) and 
patients with aneurysms that had previously recurred after 
coiling (PRET 2). The PRET trial did not show any benefit 
of hydrogel coils over bare platinum coils with respect to an 
unfavorable composite primary end point of residual/recurrent 
aneurysm, retreatment, intracranial bleeding, or mass effect 
during an 18-month follow-up period in both cohorts.14
Differences in inclusion criteria and primary end points 
among these randomized controlled trials make a head-to-
head comparison difficult (Table V in the online-only Data 
Supplement). The inclusion criteria in HELPS and PRET 
did not restrict aneurysm size, a factor known to have a 
major influence on the recurrence rate of coiled aneurysms. 
In GREAT, enrolment was restricted to patients with aneu-
rysms 4 to 12 mm in diameter. This might explain the better 
results obtained in GREAT and corroborates findings from a 
recent post hoc subgroup analysis of data from patients with 
medium-sized (5–9.9 mm) ruptured aneurysms in the HELPS 
that showed a significantly lower major recurrence rate in 
the hydrogel group than in the control group (18.6% versus 
30.8%; P=0.03) at 15 to 18 months after treatment.15
The primary end points for HELPS, PRET, and GREAT 
seem comparable. All 3 were measured at 18 months after 
the index aneurysm procedure and combined angiographic 
and clinical measures. The MAPS trial (Matrix and Platinum 
Science) used target aneurysm recurrence as a measure of 
clinical effectiveness after aneurysm treatment. Target aneu-
rysm recurrence composed of target aneurysm rupture, sud-
den unexplained death, and target aneurysm retreatment and 
is meant to capture the clinical events that are most important 
to patients after aneurysm treatment.7 In GREAT, we used a 
comparable composite end point but added angiographic mea-
sures (recurrent aneurysm).
Comparison of clinical outcomes between studies seems 
difficult because we excluded per-protocol patients with 
WFNS grade >3 from randomization into the trial. The rate 
of death or disability (mRS score ≤3) at 18 months in the 
overall group of patients treated for ruptured aneurysms was 
9.6% (19/197), which is comparable with the reported rate of 
10.5% (30/287) death or disability at 3 to 6 months follow-up 
in a subgroup of patients presenting with WFNS grades 1 to 3 
(n=287) and treated with bare platinum coils in the CLARITY 
study (Clinical and Anatomical Results in the Treatment of 
Ruptured Intracranial Aneurysms), a prospective registry 
conducted in France that included 405 patients with ruptured 
aneurysms.16 In HELPS (WFNS grades 1–3 in patients with 
ruptured aneurysms) and MAPS (WFNS grades in patients 
with ruptured aneurysms not indicated), the death or disability 
Figure 2. Subgroup analysis of composite primary end point (differences in unfavorable outcome rates in percentage). *Aneurysm size 
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rate for patients treated for ruptured aneurysms were 17.7% 
and 9.6%, respectively.7,8 The authors of the Cerecyte Coil 
Trial unfortunately did not provide corresponding data.6
In our study, the death or disability rate (mRS score ≥3) at 
18 months was 3.0% (8/270) for patients treated for unrup-
tured aneurysms, which compares favorably with the 3.1% 
rate reported at 1-month follow-up in the ATENA study 
(Analysis of Treatment by Endovascular approach of Non-
ruptured Aneurysms), a prospective registry conducted in 
France that included 649 patients treated for unruptured aneu-
rysms.17 In HELPS and MAPS, the death or disability rate 
for patients treated for unruptured aneurysms was 11.1% and 
4.2%, respectively.7,8 These favorable comparisons might be 
explained by improved materials and increased experience 
among neurointerventionalists. Another factor playing a cer-
tain role is the restriction of GREAT to aneurysms measuring 
4 to 12 mm, thereby excluding small and large aneurysms—
both known to have higher procedural complication rates. In 
addition, the inclusion of patients with ruptured aneurysms in 
GREAT was limited to WFNS grades 1 to 3, potentially influ-
encing the overall clinical outcome of the study cohort.
The inclusion of a broad international panel of treatment 
teams increased representativeness of the cohort because 12 
of 22 participating centers randomized ≥10 patients per center 
(range, 1–85).
The median packing density was significantly higher in the 
hydrogel group and seems to have translated into better long-term 
angiographic results and lower retreatment rates in our study. 
This observation corroborates findings from PRET that showed 
a correlation between packing density and angiographic recur-
rences for both the hydrogel and the control arms of that study.14
GREAT had several limitations. The generalizability of our 
findings is limited because of the restrictions in aneurysm size. 
There were more patients missing primary end point data in 
the hydrogel group (n=17) than in the control group (n=11). In 
irregularly shaped aneurysms and in aneurysms carrying mul-
tiple blebs, the ellipsoid model used for the calculation of the 
total aneurysm volume may result in inaccurately small aneu-
rysm volumes potentially exaggerating the packing density.10
The worst-case scenario analysis showed no statistically 
significant reduction in the composite end point for the sec-
ond-generation hydrogel arm compared with the bare plati-
num arm. Although some of these outcomes were missing 
for reasons unrelated to treatment, the reasons are not known 
for all patients. The clinical end point (mRS score) was self-
assessed. Because the composite outcome included morbidity 
that prevented angiographic controls, the primary end point 
is not complexity blinded to the allocated arm. The study 
was designed in December 2008; at that time, flow-diverting 
stents and intrasaccular flow disruptors had not been intro-
duced to standard interventional neuroradiology practice. 
We decided during the course of the trial to exclude patients 
treated with these novel devices from further analyses. The 
option practiced in Germany, to obtain informed consent in 
patients with WFNS grades 2 and 3 at a later stage, may have 
led to under-reporting of treatment or disease-related mor-
tality, because patients with missing informed consent were 
excluded from analysis. The follow-up period of 18 months 
was not completed by all patients; we used 6-month follow-up 
for 18% of patients.
Conclusions
Our results suggest that endovascular coil embolization with sec-
ond-generation hydrogel coils may reduce the rate of unfavor-
able outcome events, composed of major aneurysm recurrence, 
aneurysm retreatment, morbidity that prevented angiographic 
controls, and any death during treatment and follow-up in 
patients with small- and medium-sized intracranial aneurysms.
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